tbuckley/cabot-search huggingface dataset:
Suicide by rifampin overdose
Authors: R. O. Broadwell
Journal: JAMA (1978)

RIFAMPIN is a potent antibiotic with the capacity for serious and unusual side effects, even in therapeutic dosages.<sup>1,2</sup>Deaths in patients taking therapeutic dosages have been attributed to an unknown immunologic mechanism and have occurred almost exclusively in patients taking the drug at irregular intervals.<sup>3</sup>Massive overdose, "the red man syndrome," has been reported in one patient whose clinical course was uneventful.<sup>4</sup>We report the first case, to our knowledge, of rifampin overdose resulting in death after deliberate ingestion. <h3>Report of a Case</h3> A 26-year-old mentally retarded man had been well until 24 hours before admission, when considerable nausea, vomiting, and diffuse abdominal pain developed. He took magnesium sulfate with symptomatic improvement. However, within two hours of the onset of symptoms, an intense generalized pruritus developed. During the next 30 minutes, a faint, orange discoloration of the skin became apparent, and he was brought to the emergency
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas - a multicenter phase II trial (GBFiri)
Authors: J. Feisthammel, K. Schoppmeyer, M. Wiedmann, J. Zinke, J. Mossner, M. Schulze, K. Caca
Journal: Journal of Clinical Oncology (2005)

4179 Background: The majority of patients with biliary tract cancer present with advanced, unresectable tumor stages. Currently, there is no established palliative chemotherapy. Aim of this study was to evaluate the activity and tolerability of irinotecan and 5-FU/FA combination therapy (GBFiri) in patients with intrahepatic cholangiocarcinoma (CCC) or gall bladder cancer (GBC). Methods: In a prospective, non-randomized, multicenter, open-label phase II trial 21 patients with CCC or GBC are currently enrolled. Major elegibility criteria: histologic proven, measurable disease, age 18–80 years, unresectability, ECOG PS 0–2. Treatment consisted of irinotecan (80 mg/m2 i.v. over 60 min), folinic acid (500 mg/m2 over 2 hrs) and 5-FU (2000 mg/m2 continuous for 24 hrs), repeated every week for 6 weeks, followed by a 2 week interval. Treatment was continued until progression or limiting toxicity. Restaging was performed after 2 courses and response was assessed according to WHO standard criteria. Results: 21 patients were enrolled so far, 17 pts. with CCC (11 female, 4 male; median age 61 yrs) and 4 pts. with GBC (3 female, 1 male; median age 64 yrs). 21 patients are evaluable for safety and 19 for efficacy. A total of 159 doses (Median 10,6; Range 1 to 34) were administered with an overall relative dose intensitiy of 97%. 3/19 (16%) severe drug related adverse events (CTC-WHO grade 3/4) occurred: 2 leukopenias, 1 diarrhea. Response rates: CR 0/19, PR 1/19 (5%, GBC) and NC 4/19 (21%). 11/19 (58%) patients presented with disease progression at restaging. Median overall survival: CCC 166 days, GBC 461 d. Progression-free-survival: CCC 84 d, GBC 294 d. Conclusions: Irinotecan/5-FU/FA combination chemotherapy is well tolerated, but has only modest effect in patients with intrahepatic cholangiocarcinoma, while preliminary responses in gallbladder cancer are promising. Response rates and survival data on a larger GBC patient group will be presented at the meeting. No significant financial relationships to disclose.
Highlights
Journal: JAMA (2016)

Eff ect of Abaloparatide on Risk of Fracture 722In a randomized, placebo-and active-controlled trial involving 2463 postmenopausal women with osteoporosis, Miller and colleagues compared treatment with subcutaneous abaloparatide-a novel selective activator of the parathyroid hormone type 1 receptorwith placebo or open-label teriparatide for the prevention of new vertebral fractures.The authors report that compared with placebo, use of abaloparatide reduced the risk of new vertebral and nonvertebral fractures over 18 months.In an Editorial, Cappola and Shoback discuss treatment to reduce fracture risk among postmenopausal women.
Tobacco marketing. Profiteering from children
Authors: H. Waxman
Journal: JAMA (1991)

In 1946, the RJ Reynolds Tobacco Co advertised that "More Doctors Smoke Camels Than Any Other Cigarette."<sup>1</sup>Such a message conveyed that it was medically safe to smoke, and the tobacco companies targeted adults to receive that message. In 1991, tobacco companies don't use medical spokespersons to sell their products. Few physicians would attest to the safety of smoking, and tobacco companies are not as interested in adults anymore. In today's cigarette advertisements, physicians in white coats have been replaced by cartoon animals in bright, preschool colors. With straight faces, RJ Reynolds and its industry colleagues report that they've chosen figures like Old Joe Camel because they believe that such figures will appeal to adult smokers and encourage them to change brands. With the same straight faces, they will likely express shock that children respond to this campaign by taking up smoking.
Letter: Alcoholism.
Authors: W S Parker
Journal: BMJ (1974)

a live baby was made.Caesarean section through a Pfannenstiel incision revealed a posterior type III placenta praevia but no sign of accidental haemorrhage.A healthy girl was delivered.During examination of the ovaries a clot of blood was removed from the left paracolic gutter and considerable bleeding was apparent from the splenic area.A large left paramedian incision was added and the haemorrhage controlled by packs.Rapid splenectomy was then performed with double ligation of the splenic artery proximal to the aneurysmal dilatation.Recovery was uncomplicated and the patient and her daughter were discharged on the twelfth day.Ruptare of splenic artery aneurysm during
December 23/30, 1998
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aspirin Anonymous
Authors: D. B. Davies
Journal: BMJ (1961)

<h3>ABSTRACT</h3> The aim of this study was to develop a realistic network model to predict qualitatively the relationship between lockdown duration and coverage in controlling the progression of the incidence curve of an epidemic with the characteristics of COVID-19 in a closed and non-immune population. Effects of lockdown time and rate on the progression of an epidemic incidence curve in a virtual closed population of 10 thousand subjects. Predictor variables were R0 values established in the most recent literature (2.7 and 5.7), without lockdown and with coverages of 25%, 50%, and 90% for 21, 35, 70, and 140 days in 13 different scenarios for each R0, where individuals remained infected and transmitters for 14 days. We estimated model validity by applying an exponential model on the incidence curve with no lockdown, with growth rate coefficient observed in realistic scenarios. Pairwise comparisons were performed using Wilcoxon test with Bonferroni correction between peak amplitude, peak latency, and total number of cases for each R0 used. For R0=5.7, the flattening of the curve occurs only with long lockdown periods (70 and 140 days) with a 90% coverage. For R0=2.7, coverages of 25 and 50% also result in curve flattening and reduction of total cases, provided they occur for a long period (70 days or more). Short and soft lockdowns had no relevant effect on incidence or casuistry. These data corroborate the importance of lockdown duration regardless of virus transmission.
Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis
Authors: L Bassaganyas, S Beà, G Escaramís, C Tornador, I Salaverria, L Zapata, O Drechsel, P G Ferreira, B Rodriguez-Santiago, J M C Tubio, A Navarro, D Martín-García, C López, A Martínez-Trillos, A López-Guillermo, M Gut, S Ossowski, C López-Otín, E Campo, X Estivill
Journal: Leukemia (2013)
A Comparative Study of the Aptitude of the Higher Animal Organism to Acquire Immunity Throughout the Vital Cycle, and the Relation of This Aptitude to Hereditary Transmission.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Symptom Diagnosis
Authors: Richard D. Berkowitz
Journal: JAMA (1962)

An article is included for just about every symptom and sign in medicine. Each is easy to find due to logical organization and complete indexing. Most articles open with a general discussion of the symptom. This includes material such as normal variants that help in deciding whether a finding is actually an abnormality. Next, all important diseases of which the symptom is a major manifestation are listed in boldface type. For each disease so listed special characteristics of the symptom, major associated signs and symptoms, and laboratory procedures to be performed are described. Actual laboratory results are not given. The less common diseases are listed without comment at the end of the article. There are 18 tables of differential diagnosis but no illustrations.
EUTHANASIA FOR THE DEFECTIVE AND INCURABLE
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RESPIRATORY DISEASES: A SPECIAL PROVINCE OF THE GENERAL PRACTITIONER
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification and In vitro Characterization of Follicle Stimulating Hormone (FSH) Receptor Variants Associated with Abnormal Ovarian Response to FSH
Authors: Tsilya Gerasimova, Maria N. Thanasoula, Dimitrios Zattas, Emre Seli, Denny Sakkas, Maria D. Lalioti
Journal: Endocrine Reviews (2010)
[206] NEUTRAL ENDOPEPTIDASE (EC 3.4.24.11) INHIBITION BLUNTS ENDOTHELIN-1 PRODUCTION IN CIRRHOTIC RAT LIVERS: PHYSIOPATHOLOGICAL IMPLICATIONS
Authors: G. Sansoe, M. Aragno, F. Rosina, A. Smedile, M. Rizzetto, M. Parola
Journal: Journal of Hepatology (2007)
The mean predicts the number of deviants.
Journal: BMJ (1990)

because they contain added iron and vitamin D and have limited saturated fat and sodium contents, without limiting energy content.Regarding cost we can quibble over figures, but let's accept an extra cost ofE l.43 a week of using a follow on milk (or infant formula) instead of cows' milk.This is the equivalent each day of one to two disposable nappies, or a newspaper, or two cigar- ettes, or 28 ml beer.Nevertheless, for some families even this extra cost may be the proverbial straw-but the answer to this is to change other aspects of public policy, not to continue to recom- mend substandard child feeding customs that are being abandoned by many other countries in the developed world.
Abstract P4-06-16: TGF-β2, A Novel Target of CD44-Promoted Breast Cancer Invasion
Authors: I Gupta, S Madani, M Abdraboh, Riyami H Al, S Muzumdar, Z AbdElmageed, S Shanmuganathan, S Bhat, A Ramkumar, L Hakkim, A Ouhtit
Journal: Cancer Research (2012)

Abstract Background: Hyaluronan (HA) mediates communication between cancer cells and the environment via interactions with the cell surface receptor CD44. We have previously shown that CD44-HA interaction in BC cells promotes adhesion to bone marrow endothelial cells. This suggests that HA/CD44 signalling may be correlated with breast cancer (BC) metastasis. The long-term objective of this study is to increase our understanding of the mechanisms by which CD44-HA interaction promotes BC metastasis, and further identify and validate CD44-downstream transcriptional targets for anti-metastatic therapy. Materials &amp; Methods: Pursuant to this goal, we have developed a tetracycline (tet)-regulated expression of CD44 gene in the BC cell line MCF-7 (B5 clone) and identified TGF-β2 (Transforming Growth Factor beta-2; 3 fold induction) as a potential CD44s-downstream transcriptional target by microarray analysis. To further validate this finding, the same RNA samples, used for microarray analysis and their corresponding protein lysates collected from the BC cell line MCF-7-B5, were examined for CD44 expression in the presence of HA for 18, 24, and 48 hr post-tet withdrawal. Expression of TGF-β2 was examined using RT-PCR and western-Blot analyses. Results: Our results showed that TGF-β2 mRNA levels were significantly elevated following the removal of tet at 18, 24, and 48 h post-HA stimulation compared to the parental cells. Furthermore, the TGF-β2 precursor protein increased in a time-dependent pattern upon HA-stimulation and in the absence of tet. More interestingly, inhibition of CD44 gene by RNAi method decreased TGF-β2 expression upon HA-stimulation and in the absence of tet. Conclusion: Our data strongly support the hypothesis that TGF-β2 is a potential target of HA/CD44- downstream-signaling mediating BC cell invasion. Ongoing investigation aims to elucidate the signal transduction pathways coupling CD44 to the regulation of TGF-β2 expression, and further validate CD44/TGF-β2 axes in breast tumor invasion and metastasis. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-06-16.
Milwaukee deaths reignite critical issues in cervical cancer screening
Authors: R. Voelker
Journal: JAMA (1995)

GHOSTS FROM the pre—CLIA 88 era have come back to haunt technologists, physicians, and patients who rely on the sensitivity of the Papanicolaou (Pap) test for detecting cervical cancer. Last month's news reports that a cytology laboratory was charged in Milwaukee, Wis, with reckless homicide in connection with misread Pap smears has left the cytopathology community with a disturbing sense of déjà vu. "This [Milwaukee] case is similar to several other stories that first started to appear in 1987," explains Stanley L. Inhorn, MD, medical director of the Wisconsin State Laboratory of Hygiene and professor of pathology and laboratory medicine at the University of Wisconsin Medical School in Madison. "What they focus on is not that people missed the [diagnosis], but that the laboratory practice was one in which cytotechnologists were being encouraged, if not coerced, into reading large numbers of Paps, quotas were being set, and they were paying
Hepatitis C virus replication and antibody responses toward specific hepatitis C virus proteins
Authors: N Yuki
Journal: Hepatology (1994)

We assessed the correlation between hepatitis C virus replication and antibody responses toward hepatitis C virus core (C22-3), NS3 (C33C), NS4 (5-1-1 and C100-3) and NS5 proteins in 59 virus carriers. The concentration of serum hepatitis C virus RNA was determined by a competitive reverse transcription-polymerase chain reaction assay. All 50 patients with high viremic levels of ≥ 106 copies/mL had antibodies to C22-3 and C33C. Antibodies to 5-1-1, C100-3 and NS5 proteins were detected less frequently (p<0.01) in 72% (36 of 50), 78% (39 of 50) and 84% (32 of 38) of such patients, respectively. As for the nine patients with low viremic levels of<106 copies/mL, antibodies to C22-3, C33C, 5-1-1 and NS5 proteins were detected in only one patient (11%), which was significantly less than the frequency for highly viremic patients (p<0.01). Antibody to C100-3 was also found less frequently in only four patients (44%) (p<0.05). Thus, only four (44%) of the nine low viremic patients tested positive for any antibody compared with all 50 highly viremic patients (p<0.01). These results indicate that highly viremic carriers can be detected by the presence of hepatitis C virus antibodies, but a considerable proportion of low viremic carriers may not show any serological evidence of hepatitis C virus infection. (HEPATOLOGY 1994;19:1360–1365.)
Biomarkers in the Detection of Human Heritable and Germinal Mutagenesis
Authors: Mortimer L. Mendelsohn
Journal: Environmental Health Perspectives (1987)

An important potential use of biomarkers in human toxicology is the detection of induced mutational events in offspring and germ cells of exposed individuals. The importance, of course, is in risk estimation and the identification and prevention of exposure conditions that are harmful to the human genome. The challenge is to discover methods of sufficient power to find the rare, random, mutational events and to discriminate such events from other sources of molecular variation. Finding mutations is essentially a search for disorder. Normal biomarkers are inherently unsuitable in a positive search for disorder; instead one must either use abnormal markers or be prepared to search negatively, i.e., to look for and somehow validate the rare absence of a normal marker. In spite of these difficulties, there is progress to report and hope of future success in this field.
The Psychological Effects of Menstruation.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
Journal: BMJ (2007)

Objective To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom.Design Modelling cost effectiveness.Setting UK NHS.Participants Patients with relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis.Main outcome measures Cost per quality adjusted life year gained. ResultsThe base case cost per quality adjusted life year gained by using any of the four treatments ranged from £42 000 ($66 469; 61 630) to £98 000 based on efficacy information in the public domain.Uncertainty analysis suggests that the probability of any of these treatments having a cost effectiveness better than £20 000 at 20 years is below 20%.The key determinants of cost effectiveness were the time horizon, the progression of patients after stopping treatment, differential discount rates, and the price of the treatments.Conclusions Cost effectiveness varied markedly between the interventions.Uncertainty around point estimates was substantial.This uncertainty could be reduced by conducting research on the true magnitude of the effect of these drugs, the progression of patients after stopping treatment, the costs of care, and the quality of life of the patients.Price was the key modifiable determinant of the cost effectiveness of these treatments.